Posted by Michael Wonder on 08 Jan 2020
AbbVie receives Health Canada approval of Rinvoq (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis
7 January 2020 - Approval supported by efficacy and safety data from the pivotal Phase 3 SELECT rheumatoid arthritis program, one of the largest registrational Phase 3 programs in RA with approximately 4,400 patients evaluated across five studies.
AbbVie today announced that Health Canada has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (MTX).
RINVOQ is a 15 mg, once-daily oral Janus kinase (JAK) inhibitor and may be used as monotherapy or in combination with MTX or other non-biologic disease-modifying anti-rheumatic drugs.
